Research Article

Primary Bone Tumors in North of Jordan

Khaldoon M. Bashaireh1,*, Mohammed Alorjani2, Rami A. Jahmani1, Abedallah Al Khateeb1, Faisal Nimri2, Mohammad A. Al-Ebbini1, Abdel Rhaman M. Ababneh1

1Department of Special Surgery, Division of Orthopedics, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
2Department of Pathology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
3Internship, King Abdullah University Hospital, Irbid 22110, Jordan

ARTICLE INFO

Article History
Received 17 April 2020
Accepted 16 October 2020

Keywords
Bone tumor
multiple myeloma
osteochondroma
giant cell tumor

ABSTRACT

Objective: Primary tumors of bone are relatively uncommon. Little information is available about the etiology, pathophysiology, risk factors and epidemiologic features of bone tumors. In this article, we present the epidemiological data about the primary (benign and malignant) bone tumors in Jordan.

Methods: Retrospectively, we identified and assessed those patients who were diagnosed with primary bone tumor between January 2004 and December 2018 at King Abdullah University Hospital. The following information was obtained: demographics (age, sex), clinical presentation, and location of the tumor. Also, the histopathological results and finding and recurrence of the tumors were retrieved. The included primary bone tumors were those tumors fulfill the World Health Organization classification of soft tissue and bone tumors.

Results: During the study period, four-hundred and thirty-seven cases of the primary bone tumor were diagnosed in our institution. More than half of the cases were males (52.5% males and 47.5% females). In most cases, young adults are affected. The mean age for the diagnosis of giant cell tumor of bone (GCTB) is 34.1 years. The appendicular skeleton was involved in 269 (81.5%) patients while the axial skeleton in 60 patients. The most common encountered pathology is the multiple myeloma with 120 patients. After that, osteochondroma was diagnosed in 110 patients. Females were mostly affected by giant cell tumor while the osteochondroma and chondrosarcoma were seen mostly in males. Multiple myeloma tends to develop in elderly while juvenile ossifying fibroma occurred in young pediatrics and Ewing sarcoma in school-age children and adolescents. Giant cell tumor and osteoid osteoma have the tendency to recur.

Conclusion: The diagnosis of primary bone tumors is of particular important. The reporting of epidemiological studies is essential in order to expand our knowledge regarding this uncommon type of tumors.

© 2020 The Authors. Published by Atlantis Press International B.V.

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

1. INTRODUCTION

According to the World Health Organization (WHO) classification of soft tissue and bone tumor, the primary bone tumors are classified based on the origin cell of the tumor as cartilaginous tumors, osteogenic tumors, fibrogenic tumors, hematopoietic tumors, and many others [1]. Among the wide array of human neoplasms, primary tumors of bone are relatively uncommon [1,2]. Not only has this contributed to the paucity of meaningful and useful data about the relative frequency and incidence rates of the various subtypes of bone tumors, but it also explains our rudimentary understanding of risk factors.

Little information is available concerning the etiology and epidemiologic features of benign bone tumors since most published statistical studies have dealt with bone sarcomas. The benign lesions will be considered from the epidemiologic and aetiologic standpoint under the individual chapter headings, where they are known [2,3]. In this article, we present and discuss our epidemiological and diagnostic data about the primary (benign and malignant) bone tumors in Jordan.

2. MATERIALS AND METHODS

This study was conducted at King Abdullah University Hospital, a tertiary care center that is affiliated with the Jordan University of Science and Technology, located in Northern Jordan. It is the sole center for pathological diagnosis in Northern Jordan. After obtaining the Institutional Review Board approval, we retrospectively identified and assessed those patients who were diagnosed with primary bone tumor between January 2004 and December 2018. The following information was obtained: demographics (age, sex), clinical presentation, and location of the tumor. Also, the histopathological results and finding and recurrence of the tumors were retrieved.

The primary bone tumors were diagnosed according to the WHO classification of soft tissue and bone tumors.

Data were collected and entered into a spreadsheet and analyzed using appropriate software. Categorical variables were described using the frequency distribution, while continuous variables were described using the mean ± standard error of the mean.
3. RESULTS

During the study period, four-hundred and thirty-seven cases of the primary bone tumor were diagnosed in our institution. Generally, males were affected more than females (52.5% males and 47.5% females). Mostly, young adults are affected. The mean age for the diagnosis of GCTB is 34.1 years and the median are 26 years. The youngest patient was 1 year and the oldest was 90 years. The appendicular skeleton was involved in 269 (81.5%) patients while the axial skeleton in 60 patients and one patient presented with multiple involvements. The left side of the appendicular skeleton was involved in 116 patients while the right in 100 patients. The most common encountered pathology is the multiple myeloma with 120 patients. After that, osteochondroma was diagnosed in 110 patients. Also, malignant osteosarcoma, chondroblastoma, chondrosarcoma, Ewing sarcoma, fibrosarcoma, and rhabdomyosarcoma were diagnosed in 33, 6, 14, 22, 1, and 1; respectively. The most common presenting symptoms were swelling and pain. The constitutional symptoms as anemia and fatigue were dominant in multiple myeloma cases. Table 1 summarizes the general sample characteristics.

Regarding the distribution of sex within different categories, the ratio of male:female is generally equal in most types of tumor. However, females were mostly affected by giant cell tumor while the osteochondroma and chondrosarcoma were seen mostly in males. Figure 1 summarizes the distribution of sex. The mean age for most tumors was below 40. However, multiple myeloma tends to develop in the elderly after 60s as indicated by Figure 2. On the other hand, juvenile ossifying fibroma occurred in young pediatrics and Ewing sarcoma in school-age children and adolescents.

Table 2 summarizes the location distribution of each tumor. Enchondroma had a tendency to develop in the upper limb bones. The chondrosarcoma developed in the axial and lower limb along with the Ewing sarcoma. In contrast, multiple myeloma developed mostly in the axial skeleton. The osteochondroma and osteosarcoma had an exclusive tendency for the lower limb bones.

Twenty-one cases of recurrence were found after complete remission of the tumor. The mean time for recurrence was 4 years after the diagnosis of the primary tumor. Figure 3 indicates the distribution of recurrences cases. Osteoid osteoma and giant cell tumors were the most common tumors to recur after the treatment.

4. DISCUSSION

This article is a recent epidemiological study about the primary bone tumor diagnosed at King Abdullah University Hospital in Northern Jordan over 14 years and represents the population of about 2.8 million residing in this area. An old study from 1998 studied the Demographic analysis of Primary Bone Tumors of Jordan University Hospital and showed almost the same epidemiological Trend with some variation representing the increasing number of population and improved the health care quality and diagnostic modalities in Jordan. According to the WHO classification of soft tissue and bone tumors, primary bone tumors are uncommon if compared with other types of tumors that affect the human. Primary bone tumors are classified based on the origin cell of the tumor as cartilaginous tumors, osteogenic tumors, fibrogenic tumors, hematopoietic tumors, and many others. Bone sarcoma constitutes only 0.2% of all tumors [1].

The most common subtype of primary malignant bone tumors is osteosarcoma, which constitute around 35% of all cases, followed by chondrosarcoma and then Ewing sarcoma, which make 25% and 16% respectively [1–4]. In our study, osteosarcoma constitute...
7.6% of all primary bone tumors followed by Ewing sarcoma with 5% and osteochondroma with 3.2%, this make Ewing sarcoma the second most common malignant tumor and chondrosarcoma the third one, so our study showed different results than the above-mentioned distribution. These results are consistent with Rao et al. [5] in India and with Shah et al. [6] results. On the other hand, the results in western countries are different than our distribution in which the osteochondroma is more common than Ewing sarcoma [7,8]. Osteosarcoma occurred in males (51.51%) more than females (48.48%). Besides, it had more appendicular (90.6%) than axial (9.4%) involvement, and there were more cases with lower limbs (87.5%) involvement compared to upper limbs (3.1%). The mean age of diagnosis is 34.1 years. According to a study about osteosarcoma in US, males were more affected than females at all age groups and all ages [9]. Also, appendicular skeleton was involved more than axial skeleton with an obvious preference for lower limbs (74.5%) in comparison with upper limbs (11%). The incidence peaks in males at the ages of 16 and 79, whereas the peak incidence in females was at the age of 12 and 77 [9].

The incidence of primary benign bone tumors is likely underestimated because benign lesions are usually asymptomatic.
Nevertheless, they are much more common than primary malignant tumors [2–4]. According to our data, osteochondroma occurred in men (62.72%) more than women (37.27%), and it has more appendicular (94.6%) than axial (4.5%) involvement. Also, there was more cases with lower limbs (76.4%) involvement compared to upper limbs (18.2%). The mean age of diagnosis is 34.1 years. A study conducted in South China showed similar results [10]. In that study, more males (67.51%) were affected. 250 cases out of 431 had knee involvement. The mean age of diagnosis was 20.63 years [10].

The frequency of bone tumors concerning age shows a bimodal distribution, with the first peak being at the second decade. While the second peak does not occur until the sixth decade [1]. Osteosarcoma occurs predominantly in patients younger than age 20, and in this group 80% occur in long bones of the extremities [11–15]. Different types of tumors have different preferences regarding the distribution. For example, although Ewing sarcoma and osteosarcoma have similar epidemiological features, osteosarcoma occurs at the metaphysis of long bones, whereas Ewing sarcoma usually arise at the diaphysis [16–19]. Besides, age affects the primary location of bone tumors. For example, axial primary lesions were reported to be more frequent in older than in younger patients [11–19]. In the United States and Europe, giant cell tumor accounts for approximately 5% of all primary bone tumors and 21% of all benign bone tumors [20]. In China, GCTB represents 20% of all primary bone tumors [21]. GCTB occur most commonly in females in the third decade of life, between the age of 20 and 40.3 [20]. Giant cell tumor typically affects the ends of long bones, especially the distal femur, proximal tibia and fibula, and distal radius [22]. In Jordan, a study was conducted about GCTB and they found that GCTB is more common in females. Most common location is the epiphyseal/metaphyseal area around the knee. Multicentric GCTB and pulmonary metastasis were more common. Most patients were treated with intralesional curettage with or without adjuvant. Recurrence rate is 45%. Most patients showed late recurrence. Complex anatomical locations, younger age, male gender, and Campanacci grade III tumors were associated with high risk of recurrence. Some patients showed resolution of pulmonary nodules during follow-up. Denosumab was used for patients with multicentric tumors, pulmonary nodules, and recurrence. Late malignant transformation was detected in one patient with fatal outcome which warrants prolonged follow-up of GCTB [23].

Multiple myeloma is a plasma-cell disorder that is characterized by clonal proliferation of post-germinal-center B cells (malignant plasma cells) in bone marrow with the presence of monoclonal protein in the blood or urine and is accompanied with end organ dysfunction [24,25]. According to the WHO classification of soft tissue and bone tumors, multiple myeloma is considered one of the primary bone tumors [1]. To be diagnosed, multiple myeloma requires the presence of at least 10% of clonal bone marrow plasma cells, in association with the presence of monoclonal protein in blood or urine [24]. If the presence of plasmacytoma is confirmed by biopsy, the diagnosis of non-secretory myeloma can be made [26]. If symptomatic, multiple myeloma often presents with hypercalcemia, renal insufficiency, anemia, and bone disease (such as pathological fractures) [26–28]. Immediate management depends on the presence of symptoms, because studies revealed that early treatment without symptoms has no benefits [29,30].

5. CONCLUSION

Our study revealed that primary bone tumors are more common in males than females. Also, there was a significant difference between the axial and appendicular skeleton, as more tumors originated from appendicular skeleton. To be more specific, tumors originated from the lower limbs more than the upper. Furthermore, left sided tumors were more frequent than right ones. The most common complaint was feeling of a mass, that was painful in most of the cases. The most frequent histological diagnosis was multiple myeloma followed by osteochondroma.

CONFLICTS OF INTEREST

The authors declare they have no conflicts of interest.

AUTHORS’ CONTRIBUTION

All authors contributed significantly and in agreement with the content of the article. All authors were involved in project design, data collection, analysis, statistical analysis, data interpretation and writing the manuscript. All authors presented substantial contributions to the article and participated of correction and final approval of the version to be submitted.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

ETHICAL STATEMENT

This study was approved by the Institutional Review Board at the Jordan University of Science and Technology and Kind Abdulla University Hospital.

REFERENCES

[1] Fletcher CDM. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013.
[2] Niu X, Xu H, Inwards CY, Li Y, Ding Y, Douglas Letson G, et al. Primary bone tumors: epidemiologic comparison of 9200 patients treated at Beijing Ji Shui Tan Hospital, Beijing, China, with 10 165 patients at Mayo Clinic, Rochester, Minnesota. Arch Pathol Lab Med 2015;139;1149–55.
[3] Franchi A. Epidemiology and classification of bone tumors. Clin Cases Miner Bone Metab 2012;9:92–5.
[4] Wu JS, Hochman M. Bone tumors: a practical guide to imaging. New York, Dordrecht, Heidelberg, London: Springer; 2012.
[5] Rao VS, Pai MR, Rao RC, Adhikary MM. Incidence of primary bone tumours and tumour like lesions in and around Dakshina Kannada district of Karnataka. J Indian Med Assoc 1996;94;103–4, 121.
[6] Shah SH, Muzaffar S, Soomro IN, Pervez S, Hasan SH. Clinico-morphological pattern and frequency of bone cancer. J Pak Med Assoc 1999;49:110–12.

[7] Del Carmen Baena-Ocampo L, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R. Epidemiology of bone tumors in Mexico City: retrospective clinico-pathologic study of 566 patients at a referral institution. Ann Diagn Pathol 2009;13:16–21.

[8] Blackwell JB, Threlfall TJ, McCaul KA. Primary malignant bone tumours in Western Australia, 1972-1996. Pathology 2005;37:278–83.

[9] Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531–43.

[10] Tong K, Liu H, Wang X, Zhong Z, Cao S, Zhong C, et al. Osteochondroma: review of 431 patients from one medical institution in South China. J Bone Oncol 2017;8:23–9.

[11] Nagano A, Ishimaru D, Nishimoto Y, Akiyama H, Kawai A. Primary bone sarcomas in patients over 40 years of age: a retrospective study using data from the Bone Tumor Registry of Japan. J Orthop Sci 2017;22:749–54.

[12] Carisi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 2002;397:53–61.

[13] Iwata S, Ishii T, Kawai A, Hiruma T, Yonemoto T, Kamoda H, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol 2014;21:263–8.

[14] Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, et al. Osteosarcoma over the age of forty. Eur J Cancer 2003;39:157–63.

[15] Longhi A, Errani C, Gonzales-Arabi D, Ferrari C, Mercuri M. Osteosarcoma in patients older than 65 years. J Clin Oncol 2008;26:5368–73.

[16] Nishida Y, Isu K, Ueda T, Nishimoto Y, Tsuchiya H, Wada T, et al. Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group. J Surg Oncol 2009;100:48–54.

[17] Okada K, Hasegawa T, Nishida J, Ogose A, Tajino T, Osanai T, et al. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases—an experience in northern Japan. Ann Surg Oncol 2004;11:998–1004.

[18] Duffaud F, Digue L, Baciuchka-Palmaro M, Volot F, Perles-Daniel C, Garbe L, et al. Osteosarcomas of flat bones in adolescents and adults. Cancer 2000;88:324–32.

[19] Naka T, Fukuda T, Shinohara N, Iwamoto Y, Sugio Y, Tsuneyoshi M. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer 1995;76:972–84.

[20] Unni KK. Dallin's bone tumors: general aspects and data on 11,087 cases. New York: Lippincott-Raven; 1996, p. 463.

[21] Sung HW, Kao DP, Shu WP, Chai YB, Liu CC, Li SM. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am 1982;64:755–61.

[22] Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumor of bone - an overview. Arch Bone Jt Surg 2016;4:2–9.

[23] Mohaidat ZM, Al-Jamal HZ, Bany-Khalaf AM, Radaideh AM, Audat ZA. Giant cell tumor of bone: unusual features of a rare tumor. Rare Tumors 2019;11:2036361319878894.

[24] Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–60.

[25] Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860–73.

[26] Durie BGM, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379–98.

[27] Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.

[28] Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9.

[29] Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582–90.

[30] Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives, risk factors for progression, and guidelines for monitoring and management. Leukemia 2010;24:1121–7.